Despite agreeing to a number of individual Zantac lawsuit settlements and issuing a massive Zantac recall in 2020, GSK continues to argue that there is no evidence the recalled heartburn drug caused cancers among users.
Judge hopes Valsartan recall lawsuit sanctions over discovery failures will serve as a deterrent to other foreign companies considering disregard for U.S. laws.
Judges noted that the nine Zantac lawsuits involving more than 850 plaintiffs were structured in a way to avoid the need for the cases to be handled at the federal level, where all similar claims have been dismissed.
A joint report recommends that the first valsartan recall lawsuit be set to go before a jury in Fall 2024, after a prior trial scheduled to begin in March was postponed when the judge presiding over the litigation retired.
Lawyers will seek preliminary approval for a settlement of valsartan lawsuits against the generic drug maker Hetero, but claims involving other manufacturers of contaminated valsartan pills remain unresolved
Nearly 75,000 lawsuits over cancer caused by Zantac can proceed, after Delaware state court judge found that plaintiffs' expert witness testimony was sufficient for a jury to consider the claims
Verdict comes in a Zantac lawsuit against GlaxoSmithKline and Boehringer Ingelheim, weeks after Sanofi and Pfizer announced agreements to settle thousands of Zantac cancer claims.
Parties indicate they have reached a proposed settlement agreement for certain Valsartan class action lawsuits and claims involving a similar drug, irbesartan.
Glaxo first discovered a link between NDMA in Zantac and cancer at least four decades ago, according to the lawsuit filed by the independent testing lab that uncovered the cancer risks associated with the heartburn drug
GlaxoSmithKline reportedly faces the bulk of the remaining Zantac cancer lawsuits, with the first case of more than 70,000 claims currently going before a jury in Chicago.
